Johnson & Johnson (JNJ)

Medtronic is following a strategy that has worked well for Johnson & Johnson.

Analysts think this beaten-down healthcare stock will rebound.

New investors might be eager to jump in during a bull market.

This is not an exhaustive list.

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

SHCD is missing some of the healthiest dividend stocks.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

The next bear market may be your best opportunity to grow your portfolio.

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

Wall Street thinks that this robotic surgical systems leader's sell-off is overdone.

You can take these companies' dividends straight to the bank.

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

It may not be possible to avoid all risks, but it's certainly possible to minimize them.

The unlocking of SpaceX shares is reshaping the communications sector.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility. Speaking at a Deuts